Dendreons Top Five Shareholders Hold Their Breath for Big Trial Result
Summary
Investors will find out if the company has been able to show in a clinical trial whether its immune-boosting therapy for prostate cancer, Provenge, is able to prolong lives.This international bank, which got quite a bit bigger through absorbing Lehman Brothers last fall, had 6.2 million shares in Dendreon heading into this year, a 22 percent increase during the fourth quarter.The ubiquitous mutual fund operation had 3.3 million shares of Dendreon at year’s end, an 8 percent boost in its holdings in the company during the fourth quarter.The investment bank, a division of Paris-based Societe Generale, had 2.5 million shares of Dendreon on the line heading into the year.This Pasadena, CA-based equity manager had 1.8 million shares of the company heading into this year, and was the only one in the top five that sold a bit of its holdings (about 2 percent) during the fourth quarter.
Classifications
AskAI Classifications
LabelsLinked Companies
